Condition

Follicular Lymphoma (FL) clinical trials and research

• 18Clinical trials
• 31Countries

Newest Follicular Lymphoma (FL) clinical trials

All recruiting trials (18)

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• SCTB35 plus Lenalidomide for relapsed or refractory follicular lymphoma

  This trial tests whether SCTB35 given with Lenalidomide can help people whose follicular lymphoma has come back or stopped responding to prior treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07562022

• CT1182 CAR‑T infusion for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether a CT1182 CAR‑T cell infusion is safe and can help adults 18–75 with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07548697

• NexCAR19 (Talikabtagene Autoleucel) for relapsed or refractory B‑cell leukemias and lymphomas

  This trial will test modified versions of a patient's own T cells (NexCAR19/Talikabtagene Autoleucel) to see if they can control relapsed or refractory B‑cell leukemias and lymphomas in adults.

  Recruiting at 3 sites Phase 2/3 Health Institutes of Turkey · Ankara and 3 other locations · NCT07502118

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Longitudinal multi-center molecular biomarker registry for blood cancers

  This registry will collect serial blood samples and leftover tissue from people with AML or follicular lymphoma to see if molecular biomarkers predict disease course and treatment outcomes.

  Recruiting at 13 sites Tempus AI · Iowa City, Iowa and 12 other locations · NCT07154823

• Safety testing of LTZ-301 in adults with relapsed or refractory B‑cell non-Hodgkin lymphoma

  This trial will test whether LTZ-301 is safe and how it behaves in adults whose B‑cell non-Hodgkin lymphoma has come back or not responded after at least two prior treatments.

  Recruiting at 6 sites Phase 1 LTZ Therapeutics, Inc. · Duarte, California and 5 other locations · NCT07121946

• Relmacabtagene autoleucel plus sintilimab for relapsed or refractory CD19‑positive B‑cell lymphoma

  This trial will test whether giving relmacabtagene autoleucel followed by the PD‑1 drug sintilimab helps adults with relapsed or refractory CD19‑positive large B‑cell, follicular, or mantle cell lymphoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou and 2 other locations · NCT07077512

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Zanubrutinib with G-CVP for untreated Follicular Lymphoma

  This study is testing if a new combination of zanubrutinib, obinutuzumab, and chemotherapy can help people with untreated follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06959732

• Evaluating GF-CART01 for treating relapsed or refractory B-cell cancers

  This study is testing a new CAR T cell therapy called GF-CART01 to see if it can help adults with tough-to-treat B-cell cancers that haven't responded to other treatments.

  Recruiting Phase 1 GenomeFrontier Therapeutics TW Co., Ltd. · Taipei · NCT06703892

• Treatment with AZD0486 for patients with relapsed B-cell lymphoma

  This study is testing a new treatment called AZD0486 to see if it can help adults with relapsed B-cell lymphoma feel better and stay safe after trying other therapies.

  Recruiting at 80 sites Phase 2 AstraZeneca · Phoenix, Arizona and 93 other locations · NCT06526793

• Testing a new drug called odronextamab for treating follicular lymphoma

  This study is testing a new drug called odronextamab to see if it can safely and effectively treat people with follicular lymphoma who haven't received treatment before.

  Recruiting at 145 sites Phase 3 Regeneron Pharmaceuticals · Tucson, Arizona and 189 other locations · NCT06091254

• Registry platform for patients with blood cancers in Germany

  This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.

  Recruiting iOMEDICO AG · Freiburg im Breisgau · NCT06043011

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• Real-world data collection for lymphoma and patient survival

  This study is trying to gather real-life information from lymphoma patients to see how different factors affect their treatment success and long-term survival.

  Recruiting at 37 sites Hospices Civils de Lyon · Arras and 36 other locations · NCT03869619

• Treatment of advanced cancers with Mevrometostat

  This study is testing a new drug called Mevrometostat to see if it can help people with advanced cancers like small cell lung cancer, prostate cancer, and follicular lymphoma feel better and improve their treatment outcomes.

  Recruiting at 22 sites Phase 1 Pfizer · Tucson, Arizona and 84 other locations · NCT03460977

Related topics

Quick answers

How many Follicular Lymphoma (FL) clinical trials are recruiting right now?

18, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in China (7 trials), United States (7 trials), Spain (6 trials), France (4 trials), Poland (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 2: 3, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →